ABL Bio Inc. (KOSDAQ:298380)

South Korea flag South Korea · Delayed Price · Currency is KRW
173,400
+7,400 (4.46%)
At close: Nov 26, 2025
522.62%
Market Cap9.56T
Revenue (ttm)88.44B
Net Income (ttm)-28.65B
Shares Out55.13M
EPS (ttm)-575.91
PE Ration/a
Forward PE656.20
Dividendn/a
Ex-Dividend Daten/a
Volume845,167
Average Volume1,709,459
Open169,200
Previous Close166,000
Day's Range167,000 - 173,500
52-Week Range25,950 - 195,500
Beta0.74
RSI71.34
Earnings DateNov 10, 2025

About ABL Bio

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is based in Seoul, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
CEO Sang Hoon Lee
Employees 102
Stock Exchange KOSDAQ
Ticker Symbol 298380
Full Company Profile

Financial Performance

In 2024, ABL Bio's revenue was 33.40 billion, a decrease of -49.04% compared to the previous year's 65.55 billion. Losses were -55.53 billion, 1998.1% more than in 2023.

Financial Statements

News

There is no news available yet.